SEARCH

SEARCH BY CITATION

References

  • 1
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 2
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks vs. interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 142632.
  • 3
    Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36: S12834.
  • 4
    Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130: 1098106.
  • 5
    Maynard M, Pradat P, Bailly F, et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol 2006; 44: 48490.
  • 6
    Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 101523.
  • 7
    Mangia A, Ricci GL, Persico M, et al. A randomized controlled trial of pegylated interferon alfa2a (40 KD) or interferon alfa2a plus ribavirin and amantadine vs. interferon alfa2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12: 2929.
  • 8
    Thuluvath PJ, Maheshwari A, Mehdi J, et al. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine vs. interferon, ribavirin and placebo in treatment naive patients with chronic hepatitis C. Gut 2004; 53: 1305.
  • 9
    Deltenre P, Henrion J, Canva V, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004; 41: 46273.
  • 10
    Thuluvath PJ, Pande H, Maygers J. Combination therapy with interferon-alfa2b, ribavirin, and amantadine in chronic hepatitis C non-responders to interferon and ribavirin. Dig Dis Sci 2003; 48: 5947.
  • 11
    Teuber G, Pascu M, Berg T, et al. Randomized, controlled trial with IFN-alfa combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 2003; 39: 60613.
  • 12
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 6969.
  • 13
    Krawitt EL, Ashikaga T, Gordon SR, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005; 43: 2439.
  • 14
    Berg T, Kronenberger B, Hinrichsen H, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 2003; 37: 135967.
  • 15
    Hasan F, Al-Khaldi J, Asker A, et al. Peginterferon alpha-2b plus ribavirin with or without amantadine for the treatment of non-responders to standard interferon and ribavirin. Antiviral Ther 2004; 9: 499503.
  • 16
    Younossi ZM, McCullough AC, Barnes DS, et al. Pegylated interferon alfa-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci 2005; 50: 9705.
  • 17
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975.
  • 18
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346.
  • 19
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645.
  • 20
    Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK; International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98: 2354.
    Direct Link: